A preliminary study of optimal treatment response rates in patients undergoing hepatic arterial infusion chemotherapy combined with molecular targeting and immunotherapy

A preliminary study of optimal treatment response rates in patients undergoing hepatic arterial infusion chemotherapy combined with molecular targeting and immunotherapy

ObjectivesThis study aimed to examine the effectiveness of the best response rate (BRR) as a surrogate for overall survival (OS), using the modified Response Evaluation Criteria in Solid Tumors (mRECIST), in patients with unresectable hepatocellular carcinoma (HCC) undergoing hepatic arterial infusi...

Full description

Bibliographic Details
Main Authors: Mei Li, Jun Liao, Li Wang, Tianye Lv, Qianfu Sun, Yan Xu, Zhi Guo, Manman Quan, Hao Qin, Haoyang Yu, Kai Zhang, Wenge Xing, Haipeng Yu
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-04-01
Series:Frontiers in Immunology
Subjects:
targeted therapy
immunotherapy
FOLFOX-HAIC
surrogate endpoint
combination therapy
overall survival
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1303259/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1303259/full

Similar Items